WASHINGTON, DC—On November 21, the Leukemia & Lymphoma Society’s (LLS) First Runner Up for Woman of the Year, Roxana Muzzammel will present, A Meaningful Life, a benefit dinner to celebrate the research, treatment and future cure for acute myeloid leukemia (AML). Event will includes remarks by Celator Pharmaceuticals CEO, Scott Jackson, AML survivors and fighters, as well as comments by LLS National Capital Chapter Executive Director, Beth Gorman.  

 

WHO:           Roxana Muzzammel played an integralrolein LLS’2013 Man and Woman of the Year Campaign, raising nearly $100,000 to benefit blood cancer research. A Meaningful Life will not only be a celebratory dinner in honor of those who have been vital in her fundraising but also to learn about exciting new research in the quest to finding a cure to AML.

Scott Jackson, CEO of Celator Pharmaceuticals, creator of a pioneering new approach to combination chemotherapy. Jackson will share how research efforts have shown that many combinations of chemotherapeutic drugs can act synergistically to kill cancer cells when combined and maintained at certain ratios. Jackson will present the company’s Phase 3 Study of CPX-351 (cytarabine:daunorubicin) Liposome Injection, the latest treatment of AML.

Beth Gorman, theNational Capital Chapter Executive Director of LLS. Gorman will speak of LLS’ Therapy Acceleration Program (TAP)™, and how the Phase 3 study is being conducted in partnership with LLS, which has supported the development of CPX-351, beginning in Phase 2, through TAP.